CareDx, Inc.
(NASDAQ : CDNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
MDTMedtronic PLC
-1.79%93.790.6%$584.73m
ABTAbbott Laboratories
-1.95%70.770.8%$486.79m
ISRGIntuitive Surgical, Inc.
-3.99%491.812.4%$394.20m
TMOThermo Fisher Scientific Inc.
-2.96%234.201.0%$390.29m
BAXBaxter International Inc.
-1.85%65.711.7%$299.35m
BSXBoston Scientific Corporation
-3.19%35.801.1%$296.81m
ALGNAlign Technology, Inc.
-0.76%215.576.3%$291.36m
DXCMDexCom, Inc.
-1.92%120.668.5%$277.75m
BDXBecton, Dickinson and Company
-2.27%231.521.1%$262.79m
SYKStryker Corporation
-3.64%166.571.3%$228.79m
EWEdwards Lifesciences Corporation
-2.34%160.101.2%$225.73m
ABMDABIOMED, Inc.
-1.10%316.193.3%$200.61m
ZBHZimmer Biomet Holdings, Inc.
-3.01%108.981.7%$125.91m
WATWaters Corporation
-1.14%189.023.5%$107.33m
XRAYDENTSPLY International Inc.
-1.99%36.973.1%$105.68m

Company Profile

CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function and AlloSure, which is a donor-derived cell free DNA test. The firm operates through two segments: Post-Transplant and Pre-Transplant. The Post-Transplant segment is engages in development of diagnostic solutions for transplant patients. The Pre-Transplant segment develops, manufactures, markets and sells products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.